• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

RCT Results: Does Fasting Impact the Rate of GDM Screen Positive Results?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • There is some evidence to suggest that the time between last meal and the 1-hour oral glucose tolerance test (OGTT) may impact the probability of a positive screening result
  • Sperling et al. (Obstetrics & Gynecology, 2022) evaluate the effect of fasting prior to the 1-hour OGTT on gestational diabetes mellitus (GDM) screening results

METHODS:

  • Single-center, prospective randomized trial
  • Participants
    • Pregnant patients without pregestational diabetes
  • Interventions
    • Fasting: Fasting for ≥6 hours prior to testing
    • Fed: Oral intake within 2 hours of the 50-g, 1-h OGTT
  • Study design
    • The 1-h OGTT was administered >24 weeks
    • Positive screen result: Defined as a serum glucose level of ≥140 mg/dL
    • Protocol adherence was assessed by a survey administered immediately after the OGTT
    • Planned enrollment of 100 participants in each group to detect absolute difference of ≥20 percentage points on screen-positive rate | Assuming two-sided α=0.05 and power=0.8
  • Primary outcome
    • 1-h OGTT screen-positive rate
  • Secondary outcomes
    • Mean 1-h OGTT glucose values
    • GDM diagnosis
    • Maternal and neonatal outcomes
    • Patient perception of the test

RESULTS:

  • Fasting: 97 participants | Fed: 98 participants
    • Adherence to fasting: 97.9% | Adherence to fed: 91.8%
  • The screen-positive rate was significantly higher in the fasting than the fed group
    • Fasting: 32.0%
    • Fed: 13.3%
    • P=0.002
  • The mean glucose value was also higher in the fasting group
    • Fasting: 127.7 mg/dL
    • Fed: 113.3 mg/dL
    • P=0.002
  • The incidence of GDM in the fasting group was non-significantly higher than the fed group
    • Fasting: 12.4%
    • Fed: 5.1%
    • P=0.08
  • Patients were asked if given a choice between fasting or eating prior to screening
    • Preference to eat: 71.1%
    • Preference to fast: 28.9%
  • There were no significant differences in maternal or neonatal outcomes

CONCLUSION:

  • Fasting for 6 hours prior to 1-hour OGTT administration had higher screen-positive rates and greater mean glucose levels than those who ate within 2 hours of test administration
  • The authors state

…previous studies have demonstrated an increase in glucagon production and a marked delay in insulin concentration followed by a large release of insulin after a prolonged fast that eventually returns to a normal metabolic state after a period of refeeding in individuals without diabetes and those with prediabetes 

Learn More – Primary Sources:

Fasting Compared With Fed and Oral Intake Before the 1-Hour Oral Glucose Tolerance Test

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Can Immediate Glucose Tolerance Testing Postpartum Predict Results of 6-12 week GTT?
ScreenR2GDM RCT Results: One-Step vs Two-Step Screening for GDM?
Lower vs Higher Glycemic Criteria for Diagnosing GDM

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site